Home > News > PSivida losses almost all due to R&D
August 30th, 2004
PSivida losses almost all due to R&D
pSivida Limited (PSD) today reported that after deducting outside equity interest they had recorded a loss attributable to the members of pSivida of $3.6 million for financial year ending 30 June 2004, compared to a loss of $2.7 million in 2003. The consolidated entity of the global nanotechnology company incurred a net loss of $7.5 million, compared to $5.3 million in 2003. The operating loss includes $7,million in research and development costs expended by pSiMedica and administrative expenses totalling $888,961.
Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014
Acid folic was used in the production of the nanogel as targeting agent in drug delivery. The nanogel can be used in the treatment of cancer as a stable nanocarrier. Stability of nanocarriers is an important issue in target delivery mechanisms. Most of nanocarriers, due to their March 17th, 2014
Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014
Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014